Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus CUBICIN RF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus CUBICIN RF.
COR-OTICIN vs CUBICIN RF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Daptomycin is a cyclic lipopeptide antibiotic that binds to bacterial cell membranes, causing rapid depolarization and disruption of membrane potential, leading to cell death.
1-2 drops in each affected ear twice daily for 7 days.
Adults: 6 mg/kg IV over 30-60 minutes every 24 hours. For deep-seated infections (e.g., endocarditis, osteomyelitis), consider 10 mg/kg IV every 24 hours.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life: approximately 8-9 hours in patients with normal renal function; prolonged in renal impairment.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal excretion: approximately 80% of the dose as unchanged drug; biliary/fecal elimination: minor (<5%).
Category C
Category C
Topical Corticosteroid + Antibiotic
Antibiotic